Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The view from overseas on tumult in U.S. science - 18 days ago The biotech news stories you need to read today - 19 days ago The biotech news stories we’re keeping an eye on - about 2 months ago Eli Lilly seeks to join lawsuit on compounded drugs - about 2 months ago Merck is a new year outlier with its diabetes drug - about 2 months ago The biotech news you need to read today - 4 months ago Is pharma still fearful of the Inflation Reduction Act? - 7 months ago The biotech news you missed this week - 8 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 9 months ago The Senate health committee looks into its first subpoena in 40 years - about 1 year ago The biotech updates you need to read today - about 1 year ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - about 1 year ago FDA chastens pet companies over antibiotics - about 1 year ago The biotech news you missed from the weekend - about 1 year ago Novartis is building a new radioligand plant in China - about 1 year ago Johnson & Johnson bets heavy on AI-driven drug discovery - over 1 year ago Today’s biotech news roundup, in under 800 words - over 1 year ago These are the need-to-know biotech stories from this weekend - over 1 year ago Your Monday morning biotech news roundup - over 1 year ago
2	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Is Trump’s new order a reprieve for biotech? - 20 days ago The most essential and memorable JPM moments, recapped - about 2 months ago East Asians under-represented in biopharma leadership - about 2 months ago Can an epilepsy drug do more than reduce seizures? - about 2 months ago A key decision on compounding is expected this week - 3 months ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Pharma’s forecast for 2025: Sowing seeds of a rebound - about 1 month ago Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - about 2 months ago PharmaVoice’s Crystal Ball: The industry’s AI future - about 2 months ago 3 closely watched drugs that failed in the clinic - 3 months ago The big rebrand: Why these 4 biopharmas changed their name this year - 3 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 4 months ago 2024 PharmaVoice 100s: Trailblazers - 5 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 5 months ago What 3 layoff stories reveal about pharma’s troubles - 6 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 9 months ago Where competition is heating up in pharma - 9 months ago The biggest questions hanging over pharma in 2024 - about 1 year ago Pharma execs sound off on trends and policies they’re tracking in 2024 - about 1 year ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - about 1 year ago 10 of our most read articles in 2023 - about 1 year ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - over 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago
4	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: A reporter’s JPM notebook: a look ahead for biopharma VC investing - about 2 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 9 months ago
5	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	The most essential and memorable JPM moments, recapped - about 2 months ago
6	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	The most essential and memorable JPM moments, recapped - about 2 months ago
7	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years - about 2 months ago Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in - 4 months ago Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech - 4 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 4 months ago 2024 PharmaVoice 100s: Biotech Pathfinders - 4 months ago Top pharma and biotech conferences 2025 - 5 months ago Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that. - 6 months ago Will the IRA squash new drugs? Those worries are likely exaggerated, studies say. - 6 months ago A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients - 7 months ago Has pharma emerged from the ‘age of uncertainty’? - 8 months ago Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections - 8 months ago 3 up-and-coming US biotech hotspots - 10 months ago Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future - 11 months ago How to make 2024 a banner year for biopharma, despite the headwinds - about 1 year ago Biopharma’s FTC headache deepens with guideline shifts years in the making - about 1 year ago Real Chemistry’s CEO on biopharma’s outlook in 2024 - about 1 year ago A biotech tackles drug discovery with transcription factor know-how - over 1 year ago How pharma leaders talk about ethics in a highly criticized industry - over 1 year ago The thorniest questions facing pharma, according to a leading bioethicist - over 1 year ago The PharmaVoice 100: Rare disease warriors - over 1 year ago The PharmaVoice 100: Trailblazers - over 1 year ago
8	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - about 2 months ago
9	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 11 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 11 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 12 months ago
10	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 4 months ago

Journalists covering biopharma journalism